Medicare GLP-1 Bridge Enrollment Guide 2026: $50 Copay for Foundayo, Wegovy & Zepbound

The Medicare GLP-1 Bridge is a temporary CMS demonstration program that runs from July 1, 2026 through December 31, 2027. Eligible Medicare Part D beneficiaries pay a flat $50/month copay for four FDA-approved GLP-1 weight-loss drugs: Foundayo (orforglipron), Wegovy injection (semaglutide), Wegovy oral tablet (semaglutide), and Zepbound KwikPen (tirzepatide). The $50 does NOT count toward the Part D deductible or the $2,100 annual out-of-pocket cap — a structural detail that meaningfully changes the math for higher-cost Part D enrollees. Prior authorization is submitted to a CMS central processor instead of the patient's Part D plan, which standardizes the approval workflow across all plans.

Quick path to enrollment: (1) Verify Part D enrollment, (2) Document BMI and comorbidities with your prescriber, (3) Submit prior auth to the CMS central processor on or after July 1, (4) Fill at any Part D-participating pharmacy. Use our free Medicare GLP-1 Eligibility Checker to confirm eligibility in 60 seconds before you book an appointment.

What is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a short-term demonstration program announced in January 2026 and operationalized through CMS's Center for Medicare and Medicaid Innovation (CMMI). It was originally part of the broader BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) — CMS's voluntary framework to expand GLP-1 access across Medicare and Medicaid. April 2026 update: CMS canceled the BALANCE Model's Part D pilot on April 21, 2026, after major insurers — including UnitedHealthcare and CVS — declined to participate before the April 20 enrollment deadline (STAT News, Apr 21; Axios, Apr 22). The Bridge now operates independently as the sole federal Medicare GLP-1 obesity pathway. The Medicaid component of BALANCE is still moving forward — states may apply through July 31. The Bridge runs from July 1, 2026 through December 31, 2027, providing a window for Medicare Part D beneficiaries with obesity to access weight-loss GLP-1s at a predictable $50/month flat copay.

Historically, Medicare Part D excluded coverage of weight-loss drugs by statute (the original 2003 Medicare Modernization Act exclusion). The Bridge does not change that statute — it is a demonstration that operates under CMMI's authority to test alternative payment models. After December 31, 2027, the Bridge ends and access reverts to whatever permanent framework Congress and CMS have put in place by then.

Which Drugs Qualify? All Four Eligible Medications

Per the official CMS Medicare GLP-1 Bridge documentation, four drugs are covered when prescribed for chronic weight management or maintaining weight reduction. This is broader than the early reporting suggested — both manufacturers' oral pills are included, not just the injectables.

Note that Mounjaro (tirzepatide for type 2 diabetes), Ozempic (semaglutide for diabetes), and Rybelsus (oral semaglutide for diabetes) are NOT on the Bridge list. Those drugs are already covered under standard Part D for their FDA-approved diabetes indication — the Bridge specifically expands coverage for the weight-management indication of the four listed products. If you have type 2 diabetes AND obesity, your prescriber may have flexibility to prescribe Mounjaro or Ozempic under standard Part D coverage; talk to them about which pathway makes sense for your situation. For a head-to-head on the four Bridge oral options, see our Foundayo vs Wegovy Pill comparison.

Eligibility Criteria

Eligibility for the Bridge mirrors the FDA-approved labeling for chronic weight management on these four drugs, with the additional Medicare-specific requirement of Part D enrollment. To qualify, you must meet ALL of the following:

• •Medicare Part D enrolled — eligible plan types confirmed by CMS (NPR, May 6, 2026): standalone Part D plans (PDP), Medicare Advantage plans with drug coverage (MA-PD), Special Needs Plans (SNP), Employer/Union Medicare Group Waiver Plans (EGWP), and LI NET (Limited Income Newly Eligible Transition). Medicare Advantage plans WITHOUT drug coverage do not qualify.
• •BMI ≥ 30 (clinical obesity), OR
• •BMI ≥ 27 with at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, established cardiovascular disease, obstructive sleep apnea, non-alcoholic fatty liver disease, chronic kidney disease, or obesity-related joint disease
• •No FDA-listed contraindications — personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, hypersensitivity to the active ingredient, or pregnancy
• •Prescriber participation — your prescriber must be Medicare-enrolled and willing to submit the central-processor prior authorization (most are; this is similar in workflow to standard Part D PA)

How the $50 Copay Works (And Why It's Better Than It Sounds)

The $50/month copay is structurally different from a typical Part D copay in two important ways:

• •Does NOT count toward your Part D deductible. If your plan has a $590 deductible, paying $50/month for your Bridge GLP-1 leaves your deductible balance untouched. Other prescriptions still need to satisfy the deductible normally.
• •Does NOT count toward your Part D out-of-pocket cap of $2,100. The 2025 Inflation Reduction Act capped annual out-of-pocket Part D spending at $2,000 in 2025 and $2,100 in 2026. Bridge copays are excluded — meaning $50 × 12 = $600/year on a Bridge GLP-1 is in addition to your $2,100 cap, not consumed by it.

This second point is meaningful. A high-utilization Part D enrollee on multiple non-GLP-1 prescriptions could hit the $2,100 cap mid-year and pay $0 for the rest of their non-Bridge medications — and still pay only $50/month for their GLP-1 the entire time. For a typical retiree on 4-6 chronic medications, this stacking changes the practical economics significantly.

Trade-off: because Bridge spending is excluded from the OOPC cap, it does not accelerate the catastrophic-coverage threshold for any other drugs. The $50 is simply outside the standard Part D math.

How to Enroll: Step-by-Step

• •Step 1 — Confirm Part D enrollment. Log into medicare.gov or call 1-800-MEDICARE. If you're in Original Medicare with no PDP, you cannot use the Bridge — enroll in a standalone Part D plan during open enrollment (October 15 – December 7) or upon a qualifying life event. Medicare Advantage enrollees should verify their plan includes prescription drug coverage (MAPD).
• •Step 2 — Schedule a clinic visit BEFORE July 1, 2026. Your prescriber needs current BMI, weight, height, and any comorbidity diagnoses in your chart from within the past 12 months. If your last visit was longer ago than that, get an appointment on the books now.
• •Step 3 — Discuss medication choice with your prescriber. Each of the four drugs has different efficacy, side-effect, and dosing profiles. See our Wegovy vs Zepbound and Foundayo vs Wegovy Pill comparisons to prepare for the conversation. Patients with cardiovascular disease may benefit from Wegovy (which has an FDA-approved cardiovascular risk reduction indication based on the SELECT trial); patients prioritizing weight loss may lean toward Zepbound (highest trial efficacy at 20.9%); patients who can't tolerate fasting may prefer Foundayo.
• •Step 4 — Prescriber submits prior authorization to Humana (the CMS-designated central processor) on or after July 1, 2026. This is the critical workflow change. The PA does NOT go to your Part D plan — it goes to Humana's LI NET-based central processing system. CMS released the official prior authorization request form on June 8, 2026. The two-step workflow: (a) your pharmacy first runs a claim using BIN 028918 / PCN MEDDGLP1BR and receives a denial — that denial opens the PA pathway; (b) your prescriber then files the CMS form via CoverMyMeds or fax. Only prescribing clinicians can submit; patients cannot self-file. PA requests are not accepted or processed before July 1, 2026.
• •Step 5 — Fill at any Part D-participating pharmacy. Once PA is approved (typically 7-14 days), you can fill the prescription at any pharmacy that participates in your Part D plan. The $50 copay is collected at point of sale.

If your prescriber is unsure about the Bridge workflow, point them to the CMS Medicare GLP-1 Bridge resource page and the official prior authorization request form (PDF, released June 8, 2026). The form specifies the clinical criteria, the two-step pharmacy-then-prescriber workflow, and the comorbidity routing rules. CMS also published provider-facing FAQs via AMCP and prescriber-specific guidance (PDF).

The Prior Authorization Process: Central Processor, Not Your Plan

The most operationally distinctive feature of the Bridge is that prior authorization is centralized at CMS rather than distributed across each Part D plan. This solves a real problem: under standard Part D, every plan has its own PA template, criteria, and timeline, which creates inconsistent patient experiences and prescriber friction. Under the Bridge, every prescriber sends every PA to the same central processor with the same template.

CMS has designated Humana as the central processor for Bridge prior authorizations, using Humana's existing LI NET (Limited Income Newly Eligible Transition) infrastructure. This means all Part D plans — PDP, MA-PD, SNP, EGWP, LI NET — route their Bridge PAs through Humana's centralized system regardless of which plan you're enrolled in. Your prescriber submits to one processor; Humana handles the PA determination and pharmacy claim routing.

What this means for patients:

• •Predictable approval criteria. The central processor uses a single set of clinical criteria published by CMS. There is no plan-by-plan variation in BMI thresholds, comorbidity definitions, or step-therapy requirements.
• •Faster turnaround. Early CMS guidance targets a 7-14 day decision window. Standard Part D PAs can stretch to 30+ days at busy plans.
• •Plan-portable. If you switch Part D plans during open enrollment, your central-processor PA approval travels with you — you don't restart the PA clock at a new plan as you would under standard Part D coverage.
• •Appeals follow CMS pathway. Denials route to CMS reconsideration, not your Part D plan's appeals department. The standard Medicare appeals process applies (redetermination, IRE reconsideration, ALJ hearing, Medicare Appeals Council, federal court).

Program Timeline: July 2026 Through December 2027

• •May 2026 — CMS finalized operational manual and central-processor prior authorization template. Humana confirmed as central processor via LI NET infrastructure (NPR, May 6, 2026). Eligible plan types confirmed: PDP, MA-PD, SNP, EGWP, LI NET
• •June 15, 2026 — Pre-launch PA submission window opens for prescribers ready to submit on day one
• •July 1, 2026 — Bridge program LAUNCHES. First prescriptions filled. Pharmacy stock may be tight in week one
• •October 15 – December 7, 2026 — Medicare open enrollment. Switch Part D plans if your current plan is not handling Bridge claims efficiently
• •January 1, 2027 — Plan-year-2 begins. Open-enrollment changes take effect. Bridge eligibility and copay structure unchanged
• •October 15 – December 7, 2027 — Final open enrollment under the Bridge. CMS expected to publish post-Bridge transition guidance during this window
• •December 31, 2027 — Bridge program ENDS. Coverage reverts to whatever permanent framework is in place at that point

What Happens After December 31, 2027?

This is the unresolved question. The Bridge is a demonstration; it does not establish permanent Medicare coverage of weight-loss GLP-1s. Three plausible scenarios for January 1, 2028:

• •Permanent CMMI program (revised path) — CMS uses Bridge outcome data to design a new permanent CMMI program with continued GLP-1 coverage. Note: the BALANCE Part D pilot was canceled in April 2026 due to insurer non-participation; a permanent pathway would require either a new model design or Congressional action (see below).
• •Congressional action — Congress passes legislation removing the 2003 Part D weight-loss-drug exclusion, making coverage statutory and permanent. The Treat and Reduce Obesity Act has been introduced in multiple sessions; passage timing is uncertain.
• •Coverage lapses — If neither of the above happens, weight-loss GLP-1 coverage under Medicare Part D ends on December 31, 2027 and patients return to cash pay or manufacturer savings programs.

How Does the Bridge Compare to Other GLP-1 Cost Paths?

The Bridge is one of several pathways to lower-cost GLP-1 access in 2026-2027. Quick comparison of monthly out-of-pocket costs:

If you have Medicare Part D and meet the clinical criteria, the Bridge at $50/month is the cheapest legitimate pathway to FDA-approved branded GLP-1s in 2026-2027. For non-Medicare patients, see our provider rankings for the lowest-cost telehealth alternatives, including platforms with insurance navigation like Found (which actively coordinates with your insurance to determine coverage and copay) and Hers (which carries brand-name Wegovy injection and oral tablet at $149/month via the 2026 Novo Nordisk partnership — the cheapest FDA-approved Wegovy on the market).

Frequently Asked Questions

• •Can I use the Bridge if I'm under 65? — Yes, if you have Medicare due to disability (24+ months on SSDI) or end-stage renal disease, and you're enrolled in Part D. The Bridge eligibility is tied to Part D enrollment, not age.
• •Does the Bridge cover compounded GLP-1s? — No. The Bridge only covers the four FDA-approved branded products listed above. Compounded sema and tirzepatide are NOT eligible.
• •Can I use the Bridge AND a manufacturer savings card? — Generally no. Federal anti-kickback rules prohibit stacking manufacturer copay assistance with Medicare benefits. The $50 Bridge copay is your out-of-pocket; manufacturer cards do not apply on top.
• •What if my prior auth is denied? — Appeal through CMS reconsideration. Standard Medicare Part D appeals timelines apply. If you have a comorbidity that wasn't included in the original PA submission, ask your prescriber to resubmit with updated documentation.
• •Can I switch between the four drugs during the Bridge? — Yes, but each new drug requires its own prior authorization. If your prescriber wants to switch you from Wegovy injection to Zepbound, a fresh PA is submitted to the central processor.
• •Does the Bridge end if I switch Part D plans during open enrollment? — No. Your central-processor PA approval travels with you. As long as your new plan participates in Part D (which all standalone PDPs and MAPDs must), your Bridge coverage continues.
• •Is the Bridge available in all 50 states? — Yes. The Bridge is a federal Medicare program; eligibility does not vary by state. State Medicaid GLP-1 coverage is separate from the Bridge.

Sources